HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Rating Summary:
21 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
HSBC analyst Rajesh Kumar initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $13.00.
The analyst comments "As the new management team sets a clear strategy, we see Teva as lowly rated, with potential for its innovative medicine division to become a driver of growth and margin improvement. We initiate coverage on the stock with a Buy rating."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $9.98 yesterday.
You May Also Be Interested In
- Bayerische Motoren Werke AG (BMW:GR) (BMWYY) PT Lowered to EUR66 at HSBC
- Teva Pharma (TEVA) PT Raised to $57 at TD Cowen
- Barclays Downgrades Michelin (ML:FP) (MGDDY) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
HSBCSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
